Ivabradine Rowex (Ivabradine)

• Ivabradine is an If channel inhibitor used to manage conditions where heart‑rate reduction is therapeutic.
• Chronic stable angina pectoris: lowers heart rate, reducing myocardial oxygen consumption and improving exercise capacity.
• Heart failure with reduced ejection fraction: moderates heart rate to enhance ventricular filling time, which can alleviate symptoms and may improve functional status.
• Symptomatic sinus tachycardia: directly slows sinus node firing rate, providing rate control without affecting contractility.

• Ivabradine selectively binds to the funny (If) current channels in the sino‑atrial node, inhibiting the inward mixed Na⁺/K⁺ current that drives spontaneous depolarisation. By reducing this pacemaker current, the drug slows diastolic depolarisation, leading to a lower heart rate while preserving myocardial contractility and blood pressure. The effect is dose‑dependent and reversible, allowing clinicians to titrate the heart‑rate lowering effect without causing negative inotropic or vasodilatory actions.

Ivabradine may be associated with several adverse reactions, which are categorised by frequency and severity.

Common Side Effects

• Visual disturbances (phosphenes): transient luminous phenomena.
• Bradycardia: heart rate lower than intended.
• Headache.
• Dizziness.

Serious or Rare Side Effects

• Symptomatic atrial fibrillation.
• Severe bradyarrhythmias requiring medical intervention.
• Visual loss (rare retinal events).

• When prescribing ivabradine, clinicians should consider several precautionary measures to ensure safe use.
• Indication verification: confirm patient has chronic stable angina, HFrEF, or symptomatic sinus tachycardia before initiating therapy.
• Baseline heart rate: ensure resting heart rate is ≥70 bpm; avoid use if below target.
• Concomitant beta‑blockers: assess for additive bradycardia when combined with other heart‑rate‑lowering agents.
• Hepatic impairment: use with caution in moderate to severe liver disease; dose adjustment may be required.
• Pregnancy and lactation: avoid unless benefits outweigh potential risks, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Ivabradine can interact with other medicines, influencing its plasma concentration or additive heart‑rate effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels, raising risk of bradycardia.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug exposure.
• Concomitant use with other If channel inhibitors: can cause excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely)

• Beta‑blockers or calcium‑channel blockers: additive bradycardic effect; monitor heart rate.
• Digoxin: potential for increased bradycardia; observe clinical response.
• Antidepressants affecting CYP3A4 (e.g., fluoxetine): may modestly raise ivabradine concentrations.